Market research
PBYI Puma Biotechnology Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 471M
- P/E ratio
- 18.24
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 1.22
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74587V1070
- Market cap
- 471M
- P/E ratio
- 18.24
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 1.22
About
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PBYI discussion.
5 years, 4 months ago
Puma Biotechnology, Inc is currently in a long term downtrend where the price is trading 22.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Puma Biotechnology, Inc's total revenue sank by 16.5% to $53M since the same quarter in the previous year.
Its net income has dropped by 33.9% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 1116.1% to $-16M since the same quarter in the previous year.
Based on the above factors, Puma Biotechnology, Inc gets an overall score of 1/5.